63,113 Shares in DaVita Inc. (NYSE:DVA) Purchased by International Assets Investment Management LLC

International Assets Investment Management LLC purchased a new position in DaVita Inc. (NYSE:DVA) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 63,113 shares of the company’s stock, valued at approximately $10,346,000. International Assets Investment Management LLC owned about 0.07% of DaVita as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in DaVita by 1.6% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 134,823 shares of the company’s stock valued at $18,612,000 after purchasing an additional 2,129 shares during the last quarter. First Trust Direct Indexing L.P. lifted its holdings in DaVita by 3.9% during the first quarter. First Trust Direct Indexing L.P. now owns 2,590 shares of the company’s stock valued at $358,000 after purchasing an additional 98 shares during the last quarter. Janney Montgomery Scott LLC lifted its holdings in DaVita by 175.5% during the first quarter. Janney Montgomery Scott LLC now owns 18,937 shares of the company’s stock valued at $2,614,000 after purchasing an additional 12,064 shares during the last quarter. Hussman Strategic Advisors Inc. purchased a new stake in DaVita during the first quarter valued at about $2,899,000. Finally, Tokio Marine Asset Management Co. Ltd. lifted its holdings in DaVita by 11.9% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,377 shares of the company’s stock valued at $328,000 after purchasing an additional 253 shares during the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the transaction, the insider now directly owns 83,011 shares in the company, valued at $12,137,038.31. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Javier Rodriguez sold 50,000 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the sale, the chief executive officer now directly owns 837,835 shares of the company’s stock, valued at approximately $138,284,666.75. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 173,482 shares of company stock worth $27,387,069 over the last ninety days. Insiders own 2.00% of the company’s stock.

Wall Street Analyst Weigh In

DVA has been the topic of several analyst reports. Truist Financial upped their price target on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Bank of America upped their price target on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. TD Cowen upped their price target on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Finally, UBS Group upped their price target on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, DaVita has an average rating of “Hold” and an average target price of $159.00.

DaVita Stock Down 10.8 %

DVA stock opened at $141.16 on Thursday. The company has a current ratio of 1.16, a quick ratio of 1.12 and a debt-to-equity ratio of 9.94. The company’s 50 day moving average is $158.21 and its 200 day moving average is $146.02. The stock has a market cap of $11.84 billion, a price-to-earnings ratio of 15.03, a price-to-earnings-growth ratio of 0.90 and a beta of 0.87. DaVita Inc. has a 1-year low of $76.17 and a 1-year high of $168.50.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a net margin of 6.86% and a return on equity of 77.00%. The business had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. During the same quarter in the previous year, the business earned $2.85 earnings per share. The firm’s revenue was up 4.6% on a year-over-year basis. Sell-side analysts predict that DaVita Inc. will post 9.99 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.